Compounded therapies represent one of the last frontiers of true medical innovation. Clinicians are using them to address gaps left by commercial pharma—tailoring treatments for hormone balance, metabolic health, neurological recovery, immune dysfunction, and more.

But instead of investing in these advances, policymakers are tightening the screws—treating any non-FDA-approved formulation as suspect, even when it’s working.